Empowering Future Therapies: Innovations in Antibody Drug Development and Manufacturing

Abstract:

Following the FDA approval of the first ever monoclonal antibody treatment, antibodies have evolved into a mainstay of modern medicine, tackling diverse diseases from cancers to autoimmune disorders, offering improved specificity, enhanced efficacy, and reduced side effects. Following these advancements, the diversity in antibody-based therapies encompasses a wide array of therapies, including bispecific, tri-specific, antibody-drug conjugates (ADCs), and much more. Each of these advancements brings manufacturing and commercialization challenges that require innovative tools and solutions to be translated into the clinic and manufactured with FDA approval. This includes structurally accurate full-length proteins for screening, isotype controls for antibody evaluation, and enzymes for antibody characterization. For more complex therapies such as ADCs, site-specific conjugation methods can be utilized to ensure consistent and effective anti-cancer payload deliveries. Herein, we introduce various tools, solutions, and collaborations with our partners including high-throughput screening and glycobiology studies to highlight the innovative technologies and applications that enable you to develop the next generation of antibody drugs. A wide array of custom development, characterization, and scale-up manufacturing services are available to empower antibody drug development and manufacturing.

Speaker: Dr. Peter Hsueh

Peter Hsueh, Ph.D., is a dynamic Marketing Product Manager at ACROBiosystems, a leader in developing and manufacturing recombinant proteins and critical reagents/assays to support therapeutic development. Leveraging his extensive technical expertise in molecular biology and biomarker research, Peter aims in shaping impactful marketing strategies that resonate within the life science community. Formerly a Field Application Scientist, Peter brings a wealth of experience in customer technical support allowing him to understand and address the unique needs of customers. Driven by a passion for both science and marketing, Peter is committed to steering ACROBiosystems towards new horizons through targeted marketing initiatives.

Please visit Industrial Frontier Webinar Series Archive for Playback

关于华人抗体协会

华人抗体协会是一个非营利、非政府的公益性组织，是第一个也是目前唯一一个全球性华人抗体专业组织。协会侧重关注治疗性抗体，并致力于创建一个全球性平台，以促进在治疗性抗体研发，生产以及商业化等领域的合作与交流。华人抗体协会与牛津大学出版社合作，出版发行同行评审英文专业期刊: Antibody Therapeutics。

华人抗体协会网站：https://www.chineseantibody.org

华人抗体协会旗下期刊Antibody Therapeutics网站：https://academic.oup.com/abt